Enovis Corporation
ENOV · Price history
Price at last available close
$21.54
+$3.38 (+18.61%) 1M
2026-10-27
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Enovis Corporation
Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
Enovis Corporation is a global medical technology enterprise specializing in the design, production, and supply of medical devices. These specialized products are instrumental for a diverse range of healthcare professionals—including orthopedic specialists, surgeons, general physicians, pain management experts, physical therapists, podiatrists, chiropractors, and athletic trainers—who treat patients with musculoskeletal conditions resulting from degenerative illnesses, deformities, traumatic events, or sports-related injuries. The company's extensive product line encompasses rigid and flexible orthopedic supports, thermal and cryotherapy items, bone growth stimulation devices, vascular therapy systems paired with compression garments, therapeutic footwear and orthotics, electrical stimulators for pain alleviation, and physical rehabilitation equipment.
How they make money
Enovis Corporation is a medical technology company that generates revenue by developing, manufacturing, and distributing a broad portfolio of medical devices. The company sells its products primarily to healthcare providers, hospitals, and surgical centers, focusing on solutions for reconstructive surgery and other orthopedic applications to improve patient outcomes.
Products & services
Medical devices and technologies for reconstructive surgery, orthopedic bracing, and patient recovery solutions.
Brands & revenue mix
No separate brand or brand-level revenue disclosure was confirmed in the reviewed sources. This does not mean the company has no brands.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer concentration
The company does not have significant customer concentration, as no single customer accounted for more than 10% of total net sales for the fiscal year ended December 31, 2025.
Suppliers, materials & equipment
No supplier relationships were confirmed in the sources reviewed. This does not mean the company has no suppliers.
Strengths
Sources
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
20
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
20
Poor
Financial Strength
39
Business Quality / Moat
18
Management
0
Growth Quality
22
Risk / Durability
1
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
39
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
47/100
Building Historical Record
Model Score 47/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently cautious.
- •Insider activity signal is favorable
- •Debt service risk
- •M&A headline · Sep 2, 2026
- •M&A headline · Sep 1, 2026
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
Company-specific research
Questions worth answering for ENOV
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can ENOV maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •Is ENOV's positive free cash flow repeatable, or is the current level being helped by temporary working-capital or spending changes?
- •Is ENOV's debt load manageable relative to cash generation, interest costs and upcoming maturities?
- •What specifically needs to improve for ENOV to reach sustainable profitability?
- •What future growth or profitability would be needed to justify ENOV's current valuation?
Essential Investment Snapshot
Wall Street Score
20
Opportunity Score
39
Market Cap
$1.24B
P/E Ratio
-0.9
EPS
$-19.40
52-Week High
$34.28
52-Week Low
$17.30
Beta
1.43
Analyst Target
$36.00
Shares Outstanding
56.8M
Total Revenue
$2.30B
Total Debt
$1.37B
Dividend
No current dividend
Liquidation Value / Share
$26.05
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Building upward momentum
Low movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for ENOV
Detected from reported data — verify before acting.Debt service risk
Interest coverage is low (~-0.5x). Earnings may be strained to cover interest expense.
M&A headline · Sep 2, 2026
Enovis Boosts Surgical Robotics Portfolio With eCential Acquisition — This is a provider-linked headline, not an independently confirmed event. Check the article and company filings for the subject, proposed/completed status, and subsequent updates.
Zacks Investment ResearchM&A headline · Sep 1, 2026
Enovis Invests in Innovation with Binding Offer to Acquire eCential Robotics, a Leading Developer of Enabling Technologies and Surgical Robotics — This is a provider-linked headline, not an independently confirmed event. Check the article and company filings for the subject, proposed/completed status, and subsequent updates.
GlobeNewsWireCommunity Sentiment
0 active · 0 total callsNo personal call yet on ENOV.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Clinically differentiated product portfolio.
- +Focus on improving patient outcomes and clinical workflows.
- +Positive free cash flow may provide capacity to invest in growth.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Medical - Devices industry.
- −Intense competition in the medical device industry.
- −Regulatory compliance and healthcare reform impacts.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
6 historical score records availablePrevious Score
20
Sep 21, 2026
Change
Unchanged
Current Score
20
Oct 1, 2026
Category Changes
ENOV score was unchanged.
Projected Score
Projected Score
21
Projected Change
+0.6 points
Preliminary comparable-period financial changes suggest improvement of approximately 0.6 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Valuation unavailableCurrent Price
$21.54
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.30B | $2.25B | $2.11B | $1.71B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $977.6M | $902.8M | $926.9M | $716.4M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $1.32B | $1.35B | $1.18B | $990.8M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $124.3M | $120.3M | $91.3M | $75.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $1.05B | $1.07B | $939.4M | $830.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $1.22B | $1.36B | $1.96B | $1.06B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | -$716.9M | -$830.2M | -$481.0M | $169.7M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | $95.0M | -$18.9M | -$775.7M | -$65.7M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $55.5M | $34.8M | $57.1M | $19.7M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | -$1.07B | -$1.16B | -$822.9M | -$67.1M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | $30.8M | $22.3M | $4.5M | -$13.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | -$1.10B | -$1.18B | -$825.5M | -$33.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $-19.40 | $-20.86 | $-14.93 | $-0.61 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 57.60M | 56.79M | 55.28M | 54.49M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 57.60M | 56.79M | 55.28M | 54.49M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$582.8M
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$0.02
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
-6.5%
Cash Change
-71.5%
Margin Change
+6.3 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Margins expanded
- Debt reduced
What Weakened
- Cash position declined
Potential Score Impact
Positive indicators included revenue growth, debt levels, net income margin. Pressure indicators included EPS growth, cash levels. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue increased 3.2%. EPS declined 96.9%. Cash declined 71.5%. Total debt declined 6.5%. Net income margin improved by 6.3 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
24
Smart Money
24
Number of Gurus
1
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
6 historical recordsHistorical Score Chart
3 of 6 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
Medical - DevicesNews
Enovis becomes first multi-registry industry sponsor of AAOS Registry Program
Enovis (NYSE:ENOV) Hits New 52-Week Low – What’s Next?
Insider at Medical Device Maker Buys More Than 7,500 Shares
What Makes Enovis (ENOV) a New Buy Stock
Rumor Mill · ENOV
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial